Literature DB >> 3664943

The chemotherapy of advanced bladder cancer.

D W Newling1, G Stoter, R Sylvester, M de Pauw.   

Abstract

This paper traces the development of the use of chemotherapy in the management of advanced bladder carcinoma in Europe. A number of agents, including cisplatin, methotrexate, vinblastine, adriamycin, fluorouracil and cyclophosphamide, have been investigated singly and in combination in phase II studies, and it is envisaged that an ideal combination chemotherapy regimen giving lasting complete response will ultimately be used along with limited ablative surgery in the management of localised advanced bladder cancer. Careful application of the increasing knowledge of the biology of transitional cell carcinoma and strict adherence to rigid criteria of response in the assessment of new agents appears at last to offer hope of an improvement in the prognosis of invasive bladder cancer.

Entities:  

Mesh：

Year:  1987        PMID： 3664943     DOI： 10.1007/bf00262483

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  21 in total

1.  Methotrexate treatment for advanced bladder cancer.

Authors:  R R Hall; H J Bloom; J E Freeman; A Nawrocki; D M Wallace
Journal:  Br J Urol       Date:  1974-08

2.  Radical cystectomy for carcinoma of the bladder.

Authors:  P B Clark
Journal:  Br J Urol       Date:  1978-12

3.  Combination chemotherapy with adriamycin and 5-fluorouracil in advanced bladder carcinoma.

Authors:  A Veronesi; M D Magri; F Figoli; U Tirelli; E Galligioni; M G Trovò; A Merlo; V Dal Bò; S Tumolo; E Grigoletto
Journal:  Clin Oncol       Date:  1982-06

4.  Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study.

Authors:  J H Mulder; S D Fossa; M De Pauw; A T Van Oosterom
Journal:  Eur J Cancer Clin Oncol       Date:  1982-01

5.  Bladder carcinoma as a systemic disease.

Authors:  G R Prout; P P Griffin; W U Shipley
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

6.  Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer.

Authors:  A Yagoda; R C Watson; N Kemeny; W E Barzell; H Grabstald; W F Whitmore
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

7.  The management of deeply infiltrating (T3) bladder carcinoma: controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report).

Authors:  D M Wallace; H J Bloom
Journal:  Br J Urol       Date:  1976

8.  Treatment of invasive bladder cancer by local resection and high dose methotrexate.

Authors:  R R Hall; D W Newling; P D Ramsden; B Richards; M R Robinson; P H Smith
Journal:  Br J Urol       Date:  1984-12

9.  The treatment of advanced bladder cancer with methotrexate and cis-platinum--a pharmacokinetic study.

Authors:  S B Kaye; D McWhinnie; A Hart; R F Deane; P Billaert; J Welsh; R V Milsted; J F Stuart; K C Calman
Journal:  Eur J Cancer Clin Oncol       Date:  1984-02

10.  Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy.

Authors:  B Richards; J R Bastable; L Freedman; R W Glashan; G Harris; D W Newling; M R Robinson; P H Smith
Journal:  Br J Urol       Date:  1983-08
View more
  2 in total

1.  Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: a feasible and possibly effective approach.

Authors:  A Veronesi; V Dal Bo; S Morassut; A Merlo; G Carmignani; G Lo Re; A Carbone; M D Magri; R Talamini; M Francini
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 2.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.